#49977
Re: Chicharros USA - bolsa internacional
REPH
Me gusta el grafico esta a minimos y tiene GAP para cubrir
Me la estidio para entrar mañana
Me gusta el grafico esta a minimos y tiene GAP para cubrir
Me la estidio para entrar mañana
#49978
Re: Chicharros USA - bolsa internacional
Mvis
Al dólar, mañana va a ser.uj día calentito para esta accion
Al dólar, mañana va a ser.uj día calentito para esta accion
#49979
Re: Chicharros USA - bolsa internacional
Eso espero, porque vaya semana me ha dado
#49980
Re: Chicharros USA - bolsa internacional
MRKR
Malos resultados financieros, que no baten expectativas....
El valor se deja un 85% a estas horas en afters.....
Además, han tenido que retrasar el inicio del ensayo de Fase II para AML, por culpa del COVID19..
"Phase 2 AML Trial Update
Due to the COVID-19 pandemic, Marker expects to be delayed in initiating its planned Phase 2 trial in post-transplant AML patients per previously communicated timelines. Under an amended trial protocol announced in February 2020, the U.S. FDA cleared the Company to initiate the trial, beginning with a safety lead-in. Marker has paused opening the study for enrollment of the first three patients, as the manufacturing facility it utilizes to supply study drug remains closed during the pandemic. The Company continues to identify potential trial sites in the interim, in addition to establishing its own manufacturing facility. The latter portion of the safety lead-in, which involves use of a new reagent, remains on hold until the FDA reviews and accepts the final data and certificate of analysis. The alternate supplier providing these has informed the Company that it will be delayed in providing the reagent."
Por otra parte, como posible buena noticia, han anunciado un update en ASCO referente al estudio de fase 1/2 referente al cáncer de páncreas...veremos si pos aquí salvamos los platos rotos...al fin y al cabo, un retraso en el inicio de un ensayo, tampoco es ningún fracaso...
Pancreatic Cancer Data Update During ASCO
Updated data from an ongoing Phase 1/2 clinical trial being conducted with Marker's MultiTAA-specific T cell product at the Baylor College of Medicine (BCM) in patients with pancreatic adenocarcinoma will be presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO)—which due to the COVID-19 pandemic, will be held virtually. As previously reported, in the front-line treatment arm in combination with standard-of-care chemotherapy, clinical benefit was observed in correlation with the post-infusion detection of tumor-reactive T cells in patients' peripheral blood. These T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of antigen spreading. To date, there has not been any cytokine release syndrome or neurotoxicity observed in this trial.
La empresa declara tener fondos para funcionar hasta mediados de 2021.
Cash Position and Guidance: At March 31, 2020, Marker had cash and cash equivalents of $40.3 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into the second quarter of 2021.
En definitiva. a pesar de los malos resultados financieros, mantendré mi posición, que ya tenía con pérdidas del 14% al cierre de hoy, pero que no son nada en comparación al 55% que llegué a sufrir cuando apareció el tema del COVID19!!! Me pilló todo el chaparrón. Aguanté como un jabato, y aquí éstamos luchando.
Lo mismo me pasó con IMGN, y hoy ya las cierro con pérdidas tan solo del 1.8%, y con las AGEN, que las cierro hoy con pérdidas del 16%. Estas son las que quiero llevar a largo durante una buena temporada.
Un saludo
Malos resultados financieros, que no baten expectativas....
El valor se deja un 85% a estas horas en afters.....
Además, han tenido que retrasar el inicio del ensayo de Fase II para AML, por culpa del COVID19..
"Phase 2 AML Trial Update
Due to the COVID-19 pandemic, Marker expects to be delayed in initiating its planned Phase 2 trial in post-transplant AML patients per previously communicated timelines. Under an amended trial protocol announced in February 2020, the U.S. FDA cleared the Company to initiate the trial, beginning with a safety lead-in. Marker has paused opening the study for enrollment of the first three patients, as the manufacturing facility it utilizes to supply study drug remains closed during the pandemic. The Company continues to identify potential trial sites in the interim, in addition to establishing its own manufacturing facility. The latter portion of the safety lead-in, which involves use of a new reagent, remains on hold until the FDA reviews and accepts the final data and certificate of analysis. The alternate supplier providing these has informed the Company that it will be delayed in providing the reagent."
Por otra parte, como posible buena noticia, han anunciado un update en ASCO referente al estudio de fase 1/2 referente al cáncer de páncreas...veremos si pos aquí salvamos los platos rotos...al fin y al cabo, un retraso en el inicio de un ensayo, tampoco es ningún fracaso...
Pancreatic Cancer Data Update During ASCO
Updated data from an ongoing Phase 1/2 clinical trial being conducted with Marker's MultiTAA-specific T cell product at the Baylor College of Medicine (BCM) in patients with pancreatic adenocarcinoma will be presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO)—which due to the COVID-19 pandemic, will be held virtually. As previously reported, in the front-line treatment arm in combination with standard-of-care chemotherapy, clinical benefit was observed in correlation with the post-infusion detection of tumor-reactive T cells in patients' peripheral blood. These T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of antigen spreading. To date, there has not been any cytokine release syndrome or neurotoxicity observed in this trial.
La empresa declara tener fondos para funcionar hasta mediados de 2021.
Cash Position and Guidance: At March 31, 2020, Marker had cash and cash equivalents of $40.3 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into the second quarter of 2021.
En definitiva. a pesar de los malos resultados financieros, mantendré mi posición, que ya tenía con pérdidas del 14% al cierre de hoy, pero que no son nada en comparación al 55% que llegué a sufrir cuando apareció el tema del COVID19!!! Me pilló todo el chaparrón. Aguanté como un jabato, y aquí éstamos luchando.
Lo mismo me pasó con IMGN, y hoy ya las cierro con pérdidas tan solo del 1.8%, y con las AGEN, que las cierro hoy con pérdidas del 16%. Estas son las que quiero llevar a largo durante una buena temporada.
Un saludo
#49981
Re: Chicharros USA - bolsa internacional
Yo AYTU la dejo ahí, el jueves dan resultados, creo que va a tener mas recorrido estos días, venderla ahora pienso que es un error.
Yo la llevo 1,5
Yo la llevo 1,5
#49982
Re: Chicharros USA - bolsa internacional
A ver si sube un poco más el dólar con respecto al euro y saco beneficios extra.
Yo no se vosotros pero yo lo noto mucho en mi cartera
Yo no se vosotros pero yo lo noto mucho en mi cartera
#49983
Re: Chicharros USA - bolsa internacional
Ayer en el after ya estaba a 3, aunque imagino que corregirá antes de abrir hoy. Creo que es un patrón en V
#49984
Re: Chicharros USA - bolsa internacional
Mvis hasta cuando la vais a aguantar